61 related articles for article (PubMed ID: 38727266)
1. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma.
Okuno K; Xu C; Pascual-Sabater S; Tokunaga M; Han H; Fillat C; Kinugasa Y; Goel A
Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297310
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.
Shrestha P; Ghanwatkar Y; Mahto S; Pramanik N; Mahato RI
ACS Appl Mater Interfaces; 2024 May; ():. PubMed ID: 38813771
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Epithelial-Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel.
Nakamura H; Watanabe M; Takada K; Sato T; Hikage F; Umetsu A; Muramatsu J; Furuhashi M; Ohguro H
Biomedicines; 2024 May; 12(5):. PubMed ID: 38790973
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment Modulates Invadopodia Activity of Non-Selected and Acid-Selected Pancreatic Cancer Cells and Its Sensitivity to Gemcitabine and C18-Gemcitabine.
Carvalho TMA; Audero MM; Greco MR; Ardone M; Maggi T; Mallamaci R; Rolando B; Arpicco S; Ruffinatti FA; Pla AF; Prevarskaya N; Koltai T; Reshkin SJ; Cardone RA
Cells; 2024 Apr; 13(9):. PubMed ID: 38727266
[TBL] [Abstract][Full Text] [Related]
5. DRMref: comprehensive reference map of drug resistance mechanisms in human cancer.
Liu X; Yi J; Li T; Wen J; Huang K; Liu J; Wang G; Kim P; Song Q; Zhou X
Nucleic Acids Res; 2024 Jan; 52(D1):D1253-D1264. PubMed ID: 37986230
[TBL] [Abstract][Full Text] [Related]
6. Acidic Growth Conditions Promote Epithelial-to-Mesenchymal Transition to Select More Aggressive PDAC Cell Phenotypes In Vitro.
Audero MM; Carvalho TMA; Ruffinatti FA; Loeck T; Yassine M; Chinigò G; Folcher A; Farfariello V; Amadori S; Vaghi C; Schwab A; Reshkin SJ; Cardone RA; Prevarskaya N; Fiorio Pla A
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174038
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between tumor acidosis, p53 and extracellular matrix regulates pancreatic cancer aggressiveness.
Czaplinska D; Ialchina R; Andersen HB; Yao J; Stigliani A; Dannesboe J; Flinck M; Chen X; Mitrega J; Gnosa SP; Dmytriyeva O; Alves F; Napp J; Sandelin A; Pedersen SF
Int J Cancer; 2023 Mar; 152(6):1210-1225. PubMed ID: 36408933
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
[TBL] [Abstract][Full Text] [Related]
9. DRESIS: the first comprehensive landscape of drug resistance information.
Sun X; Zhang Y; Li H; Zhou Y; Shi S; Chen Z; He X; Zhang H; Li F; Yin J; Mou M; Wang Y; Qiu Y; Zhu F
Nucleic Acids Res; 2023 Jan; 51(D1):D1263-D1275. PubMed ID: 36243960
[TBL] [Abstract][Full Text] [Related]
10. Acid Adaptation Promotes TRPC1 Plasma Membrane Localization Leading to Pancreatic Ductal Adenocarcinoma Cell Proliferation and Migration through Ca
Schnipper J; Kouba S; Hague F; Girault A; Telliez MS; Guénin S; Ahidouch A; Pedersen SF; Ouadid-Ahidouch H
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230869
[TBL] [Abstract][Full Text] [Related]
11. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.
Morgan E; Soerjomataram I; Rumgay H; Coleman HG; Thrift AP; Vignat J; Laversanne M; Ferlay J; Arnold M
Gastroenterology; 2022 Sep; 163(3):649-658.e2. PubMed ID: 35671803
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.
Koltai T; Reshkin SJ; Carvalho TMA; Di Molfetta D; Greco MR; Alfarouk KO; Cardone RA
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626089
[TBL] [Abstract][Full Text] [Related]
13. Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment.
Wu TC; Liao CY; Lu WC; Chang CR; Tsai FY; Jiang SS; Chen TH; Lin KM; Chen LT; Chang WW
J Exp Clin Cancer Res; 2022 Apr; 41(1):137. PubMed ID: 35410237
[TBL] [Abstract][Full Text] [Related]
14. Impact of Extracellular pH on Apoptotic and Non-Apoptotic TRAIL-Induced Signaling in Pancreatic Ductal Adenocarcinoma Cells.
Hagelund S; Trauzold A
Front Cell Dev Biol; 2022; 10():768579. PubMed ID: 35281089
[TBL] [Abstract][Full Text] [Related]
15. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.
Carvalho TMA; Di Molfetta D; Greco MR; Koltai T; Alfarouk KO; Reshkin SJ; Cardone RA
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885243
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Cancer: A Review.
Park W; Chawla A; O'Reilly EM
JAMA; 2021 Sep; 326(9):851-862. PubMed ID: 34547082
[TBL] [Abstract][Full Text] [Related]
17. GDP Induces PANC-1 Human Pancreatic Cancer Cell Death Preferentially under Nutrient Starvation by Inhibiting PI3K/Akt/mTOR/Autophagy Signaling Pathway.
Sun S; Kim MJ; Omar AM; Duy Phan N; Aoike M; Awale S
Chem Biodivers; 2021 Sep; 18(9):e2100389. PubMed ID: 34213070
[TBL] [Abstract][Full Text] [Related]
18. Emerging strategies for treating metastasis.
Esposito M; Ganesan S; Kang Y
Nat Cancer; 2021 Mar; 2(3):258-270. PubMed ID: 33899000
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
